Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinoma 1Subcutaneous panniculitis-like T-cell lymphoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Breast Cancer Organoids 1

Interventions

Cyclophosphamide 7Doxorubicin 5Vincristine 4fludarabine phosphate 3Gemcitabine 3Alemtuzumab 3Psychiatric Rehabilitation 2Prednisone 2Prednisolone 2Mycophenolic Acid 2Methylprednisolone 2Flow Cytometry 2Cyclosporine 2Cisplatin 2Antilymphocyte Serum 2spartalizumab 1sargramostim 1romidepsin 1prednylidene 1pirarubicin 1motesanib diphosphate 1etoposide phosphate 1Therapeutics 1Thalidomide 1Sensitivity and Specificity 1Rituximab 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Immunoblastic Lymphadenopathy × pirarubicin × Clear all
NCT01746992 2017-11-14

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Ruijin Hospital

Phase 4 Unknown
200 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡